|
|
|
Volumn 27, Issue 2, 2000, Pages 204-212
|
|
Cytokine combinations: Therapeutic use in patients with advanced renal cell carcinoma
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ALPHA INTERFERON;
ANTINEOPLASTIC AGENT;
BETA INTERFERON;
CYCLOPHOSPHAMIDE;
CYTOKINE;
FLUOROURACIL;
GAMMA INTERFERON;
GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR;
INTERLEUKIN 4;
PYRIMIDINE DERIVATIVE;
RECOMBINANT INTERLEUKIN 2;
TAMOXIFEN;
TUMOR NECROSIS FACTOR ALPHA;
CANCER COMBINATION CHEMOTHERAPY;
CANCER IMMUNOTHERAPY;
CANCER SURVIVAL;
DRUG INDUCED DISEASE;
FEVER;
GASTROINTESTINAL TOXICITY;
HUMAN;
HYPOTENSION;
KIDNEY CARCINOMA;
LYMPHOKINE ACTIVATED KILLER CELL;
NATURAL KILLER CELL;
PRIORITY JOURNAL;
REVIEW;
T LYMPHOCYTE SUBPOPULATION;
TREATMENT OUTCOME;
ADJUVANTS, IMMUNOLOGIC;
ANIMALS;
ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;
CARCINOMA, RENAL CELL;
CLINICAL TRIALS;
COMBINED MODALITY THERAPY;
FLUOROURACIL;
HUMANS;
INTERFERON-BETA;
INTERLEUKIN-2;
KIDNEY NEOPLASMS;
LYMPHOCYTE SUBSETS;
NEOPLASM METASTASIS;
PROGNOSIS;
RANDOMIZED CONTROLLED TRIALS;
RECOMBINANT PROTEINS;
REMISSION INDUCTION;
TUMOR NECROSIS FACTOR-ALPHA;
|
|
EID: 0034074165
PISSN: 00937754
EISSN: None
Source Type: Journal
DOI: None Document Type: Review |
|
Times cited : (56)
|
|
References (66)
|
